Global Acromegaly Gigantism Treatment Market
Global Acromegaly Gigantism Treatment Market

Acromegaly Gigantism Treatment Comprehensive Study by Type (Somatostatin analogs, GHRA), End Use (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2026

Acromegaly Gigantism Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2022 Edition 206 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Acromegaly is defined as a hormonal disorder that helps to develops pituitary to produce an excessive amount of somatotropin during adulthood. once you have an excessive amount of somatotropin , your bones increase in size. In childhood, this results in increased height and is named gigantism. But in adulthood, a change tall doesn't occur.This growth is primarily driven by Rising prevalence disease.

Globally, a noticeable market trend is evident Growing popularity of treatment over surgeries. Major Players, such as Ipsen (France), Novartis (Switzerland), Pfizer (United States), Glide Pharmaceutical (United Kingdom), Aegis Therapeutics (United States), Chaisma (United States), Crinetics Pharmaceuticals (United States), Daewoong Pharmaceutical (South Korea), Peptron (South Korea) and Silence Therapeutics (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In 2020, FDA approves oral therapy for acromegaly which is helps for long-term maintenance therapy for people. Octreotide injection is the first and only oral somatostatin analogue approved by the FDA.

Market Drivers
  • Rising prevalence disease

Market Trend
  • Growing popularity of treatment over surgeries

Restraints
  • High cost of treatment

Opportunities
Due to the growing population and increasing diabetic patients and growing healthcare facilities in developing nations and advanced treatment options
Challenges
Difficulty to do treatment

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Acromegaly Gigantism Treatment Study Sheds Light on
— The Acromegaly Gigantism Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Acromegaly Gigantism Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Acromegaly Gigantism Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Acromegaly Gigantism Treatment Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Acromegaly Gigantism Treatment Market?
Companies that are profiled in Global Acromegaly Gigantism Treatment Market are Ipsen (France), Novartis (Switzerland), Pfizer (United States), Glide Pharmaceutical (United Kingdom), Aegis Therapeutics (United States), Chaisma (United States), Crinetics Pharmaceuticals (United States), Daewoong Pharmaceutical (South Korea), Peptron (South Korea) and Silence Therapeutics (United Kingdom) etc.

3. What is Acromegaly Gigantism Treatment Market?
Acromegaly is defined as a hormonal disorder that helps to develops pituitary to produce an excessive amount of somatotropin during adulthood. once you have an excessive amount of somatotropin , your bones increase in size. In childhood, this results in increased height and is named gigantism. But in adulthood, a change tall doesn't occur.
Report Objectives / Segmentation Covered
By Type
  • Somatostatin analogs
  • GHRA
By End Use
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence disease
    • 3.3. Market Challenges
      • 3.3.1. Difficulty to do treatment
    • 3.4. Market Trends
      • 3.4.1. Growing popularity of treatment over surgeries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acromegaly Gigantism Treatment, by Type, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Acromegaly Gigantism Treatment (Value)
      • 5.2.1. Global Acromegaly Gigantism Treatment by: Type (Value)
        • 5.2.1.1. Somatostatin analogs
        • 5.2.1.2. GHRA
      • 5.2.2. Global Acromegaly Gigantism Treatment by: End Use (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Acromegaly Gigantism Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Acromegaly Gigantism Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ipsen (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Glide Pharmaceutical (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Aegis Therapeutics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Chaisma (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Crinetics Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Daewoong Pharmaceutical (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Peptron (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Silence Therapeutics (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Acromegaly Gigantism Treatment Sale, by Type, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Acromegaly Gigantism Treatment (Value)
      • 7.2.1. Global Acromegaly Gigantism Treatment by: Type (Value)
        • 7.2.1.1. Somatostatin analogs
        • 7.2.1.2. GHRA
      • 7.2.2. Global Acromegaly Gigantism Treatment by: End Use (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Acromegaly Gigantism Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acromegaly Gigantism Treatment: by Type(USD Million)
  • Table 2. Acromegaly Gigantism Treatment Somatostatin analogs , by Region USD Million (2015-2020)
  • Table 3. Acromegaly Gigantism Treatment GHRA , by Region USD Million (2015-2020)
  • Table 4. Acromegaly Gigantism Treatment: by End Use(USD Million)
  • Table 5. Acromegaly Gigantism Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 6. Acromegaly Gigantism Treatment Clinics , by Region USD Million (2015-2020)
  • Table 7. Acromegaly Gigantism Treatment Others , by Region USD Million (2015-2020)
  • Table 8. South America Acromegaly Gigantism Treatment, by Country USD Million (2015-2020)
  • Table 9. South America Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 10. South America Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 11. Brazil Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 12. Brazil Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 13. Argentina Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 14. Argentina Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 15. Rest of South America Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 16. Rest of South America Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 17. Asia Pacific Acromegaly Gigantism Treatment, by Country USD Million (2015-2020)
  • Table 18. Asia Pacific Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 19. Asia Pacific Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 20. China Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 21. China Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 22. Japan Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 23. Japan Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 24. India Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 25. India Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 26. South Korea Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 27. South Korea Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 28. Taiwan Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 29. Taiwan Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 30. Australia Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 31. Australia Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 32. Rest of Asia-Pacific Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 33. Rest of Asia-Pacific Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 34. Europe Acromegaly Gigantism Treatment, by Country USD Million (2015-2020)
  • Table 35. Europe Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 36. Europe Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 37. Germany Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 38. Germany Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 39. France Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 40. France Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 41. Italy Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 42. Italy Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 43. United Kingdom Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 44. United Kingdom Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 45. Netherlands Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 46. Netherlands Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 47. Rest of Europe Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 48. Rest of Europe Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 49. MEA Acromegaly Gigantism Treatment, by Country USD Million (2015-2020)
  • Table 50. MEA Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 51. MEA Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 52. Middle East Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 53. Middle East Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 54. Africa Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 55. Africa Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 56. North America Acromegaly Gigantism Treatment, by Country USD Million (2015-2020)
  • Table 57. North America Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 58. North America Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 59. United States Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 60. United States Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 61. Canada Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 62. Canada Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 63. Mexico Acromegaly Gigantism Treatment, by Type USD Million (2015-2020)
  • Table 64. Mexico Acromegaly Gigantism Treatment, by End Use USD Million (2015-2020)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Acromegaly Gigantism Treatment: by Type(USD Million)
  • Table 76. Acromegaly Gigantism Treatment Somatostatin analogs , by Region USD Million (2021-2026)
  • Table 77. Acromegaly Gigantism Treatment GHRA , by Region USD Million (2021-2026)
  • Table 78. Acromegaly Gigantism Treatment: by End Use(USD Million)
  • Table 79. Acromegaly Gigantism Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 80. Acromegaly Gigantism Treatment Clinics , by Region USD Million (2021-2026)
  • Table 81. Acromegaly Gigantism Treatment Others , by Region USD Million (2021-2026)
  • Table 82. South America Acromegaly Gigantism Treatment, by Country USD Million (2021-2026)
  • Table 83. South America Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 84. South America Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 85. Brazil Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 86. Brazil Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 87. Argentina Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 88. Argentina Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 89. Rest of South America Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 90. Rest of South America Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 91. Asia Pacific Acromegaly Gigantism Treatment, by Country USD Million (2021-2026)
  • Table 92. Asia Pacific Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 93. Asia Pacific Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 94. China Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 95. China Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 96. Japan Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 97. Japan Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 98. India Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 99. India Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 100. South Korea Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 101. South Korea Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 102. Taiwan Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 103. Taiwan Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 104. Australia Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 105. Australia Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 106. Rest of Asia-Pacific Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 107. Rest of Asia-Pacific Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 108. Europe Acromegaly Gigantism Treatment, by Country USD Million (2021-2026)
  • Table 109. Europe Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 110. Europe Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 111. Germany Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 112. Germany Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 113. France Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 114. France Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 115. Italy Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 116. Italy Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 117. United Kingdom Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 118. United Kingdom Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 119. Netherlands Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 120. Netherlands Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 121. Rest of Europe Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 122. Rest of Europe Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 123. MEA Acromegaly Gigantism Treatment, by Country USD Million (2021-2026)
  • Table 124. MEA Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 125. MEA Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 126. Middle East Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 127. Middle East Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 128. Africa Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 129. Africa Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 130. North America Acromegaly Gigantism Treatment, by Country USD Million (2021-2026)
  • Table 131. North America Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 132. North America Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 133. United States Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 134. United States Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 135. Canada Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 136. Canada Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 137. Mexico Acromegaly Gigantism Treatment, by Type USD Million (2021-2026)
  • Table 138. Mexico Acromegaly Gigantism Treatment, by End Use USD Million (2021-2026)
  • Table 139. Research Programs/Design for This Report
  • Table 140. Key Data Information from Secondary Sources
  • Table 141. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acromegaly Gigantism Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Acromegaly Gigantism Treatment: by End Use USD Million (2015-2020)
  • Figure 6. South America Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 7. Asia Pacific Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 8. Europe Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 9. MEA Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 10. North America Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 11. Global Acromegaly Gigantism Treatment share by Players 2020 (%)
  • Figure 12. Global Acromegaly Gigantism Treatment share by Players (Top 3) 2020(%)
  • Figure 13. Global Acromegaly Gigantism Treatment share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 16. Ipsen (France) Revenue: by Geography 2020
  • Figure 17. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 19. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer (United States) Revenue: by Geography 2020
  • Figure 21. Glide Pharmaceutical (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Glide Pharmaceutical (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Aegis Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 24. Aegis Therapeutics (United States) Revenue: by Geography 2020
  • Figure 25. Chaisma (United States) Revenue, Net Income and Gross profit
  • Figure 26. Chaisma (United States) Revenue: by Geography 2020
  • Figure 27. Crinetics Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 28. Crinetics Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 29. Daewoong Pharmaceutical (South Korea) Revenue, Net Income and Gross profit
  • Figure 30. Daewoong Pharmaceutical (South Korea) Revenue: by Geography 2020
  • Figure 31. Peptron (South Korea) Revenue, Net Income and Gross profit
  • Figure 32. Peptron (South Korea) Revenue: by Geography 2020
  • Figure 33. Silence Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Silence Therapeutics (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Global Acromegaly Gigantism Treatment: by Type USD Million (2021-2026)
  • Figure 36. Global Acromegaly Gigantism Treatment: by End Use USD Million (2021-2026)
  • Figure 37. South America Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 38. Asia Pacific Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 39. Europe Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 40. MEA Acromegaly Gigantism Treatment Share (%), by Country
  • Figure 41. North America Acromegaly Gigantism Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Ipsen (France)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • Glide Pharmaceutical (United Kingdom)
  • Aegis Therapeutics (United States)
  • Chaisma (United States)
  • Crinetics Pharmaceuticals (United States)
  • Daewoong Pharmaceutical (South Korea)
  • Peptron (South Korea)
  • Silence Therapeutics (United Kingdom)
Additional players considered in the study are as follows:
Strongbridge Biopharma (United States) , Amryt Pharma (United Kingdom) , Foresee Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation